http://www.gene.com/gene/products/in...p#pharmacology
I found this information on the Genentech website---look under the DESCRIPTION section.
-----------------------------------------------------------------------
DESCRIPTION
HERCEPTIN (Trastuzumab) is a recombinant DNA-derived humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2<SUP>
1,
2</SUP>. The antibody is an IgG<SUB>1</SUB> kappa that contains human framework regions with the complementarity-determining regions of a murine antibody (4D5) that binds to HER2.
The humanized antibody against HER2 is produced by a mammalian cell (Chinese Hamster Ovary [CHO]) suspension culture in a nutrient medium containing the antibiotic gentamicin. Gentamicin is not detectable in the final product.
HERCEPTIN is a sterile, white to pale yellow, preservative-free lyophilized powder for intravenous (IV) administration. The nominal content of each HERCEPTIN vial is 440 mg Trastuzumab, 400 mg
,
-trehalose dihydrate, 9.9 mg L-histidine HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP.
Reconstitution with 20 mL of the supplied Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative, yields a multi-dose solution containing 21 mg/mL Trastuzumab, at a pH of approximately 6.
---------------------------------------------------------------------
Also:
http://www.moleculartherapies.com/
<SMALL>
Posted By Jane Chin, Ph.D.
[ Permalink ] [ Bookmark on del.icio.us ] [ Add to Google ] [ Comments (1) » ]</SMALL>
- Trastuzumab (Herceptin® Official Website :: Targeting Tumors :: Latest News )
- What It Is: Recombinant DNA-derived humanized monoclonal antibody.
- Target: Extracellular domain of the human epidermal growth factor receptor 2 protein, HER2.
- Source: Humanized antibody against HER2 produced by Chinese Hamster Ovary (CHO) suspension culture.
- Approved Indications: Combination adjuvant treatment of HER2‑overexpressing, node‑positive breast cancer, single agent therapy of metastatic breast cancer overexpressing the HER2 protein with prior chemotherapy for metastatic disease, First-line combination treatment of metastatic breast cancer overexpressing HER2 protein. See Package Insert.
- Currently Active Clinical Trials from ClinicalTrials.gov.
-------------------------------------------------------------------
And:
http://www.nlm.nih.gov/medlineplus/d...r/a699019.html
Before administering trastuzumab,
- tell your doctor and pharmacist if you are allergic to trastuzumab, Chinese hamster ovary cell proteins, benzyl alcohol, or any other drugs.